Top

Osteoporosis International

Published in:

01-03-2010 | Case Report

Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases

Authors: W. Park, N.-K. Kim, M.-Y. Kim, Y.-M. Rhee, H. J. Kim

Published in: Osteoporosis International | Issue 3/2010

Abstract

Summary

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) can occur irrespective of race. Old age and long-term use of corticosteroid may be a more reliable risk factor than racial characteristics.

Introduction

BRONJ is an increasingly common problem. Most BRONJ occurs following an intravenous administration of bisphosphonate treatment for malignant bone disease and metastatic cancer. As the incidence of BRONJ caused by oral administration of bisphosphonate is quite low, it is believed that this medication is relatively safe and effective in preventing complications of osteoporosis, such as hip or spine fractures. The many known risk factors for BRONJ can be classified as drug-related, local, demographic, and systemic. One demographic and systemic risk factor is race. Most of the case reports of BRONJ present elderly, white women.

Methods

In this report, we describe five cases of BRONJ caused by oral administration of bisphosphonate in Asian population.

Results

All the patients were female and over 65 years old. Three patients had been prescribed with corticosteroids for rheumatoid arthritis.

Conclusion

Irrespective of race, elderly women undergoing steroid therapy have an increased incidence of BRONJ even with oral administration of bisphosphonate.

Body JJ (2006) Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 12:6258s–6263sCrossRefPubMed

Lipton A (2007) Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 7(Suppl 1):S14–S20CrossRefPubMed

Wu S, Dahut WL, Gulley JL (2007) The use of bisphosphonates in cancer patients. Acta Oncol 46:581–591CrossRefPubMed

Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778CrossRefPubMed

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD004523

Marx RE (2008) Bisphosphonate-induced osteonecrosis of the jaws: a challenge, a responsibility, and an opportunity. Int J Periodontics Restor Dent 28:5–6

Bertoldo F, Santini D, Lo Cascio V (2007) Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 4:711–721CrossRefPubMed

Ruggiero SL, Drew SJ (2007) Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86:1013–1021CrossRefPubMed

American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137:1144–1150

10.

Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–441CrossRefPubMed

11.

AAOMS (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376CrossRef

12.

Sawatari Y, Marx RE (2007) Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 19:487–498 v-viCrossRefPubMed

13.

Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558CrossRefPubMed

14.

Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRefPubMed

15.

Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, Badalamenti G, Russo A, Gebbia N (2007) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol 18:vi168–vi172CrossRefPubMed

16.

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841–847CrossRefPubMed

17.

Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, Tregnaghi A, Pietrogrande F, Procopio O, Saia G, Ferretti M, Bedogni G, Chiarini L, Ferronato G, Ninfo V, Lo Russo L, Lo Muzio L, Nocini PF (2008) Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:358–364CrossRefPubMed

18.

Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M (2007) Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:249–258CrossRefPubMed

19.

Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G, Fontanella W, Pignataro L (2007) Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103:e1–e5CrossRefPubMed

20.

Dimitrakopoulos I, Magopoulos C, Karakasis D (2006) Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 35:588–593CrossRefPubMed

21.

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMed

22.

Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefPubMed

23.

Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMed

24.

Bertoldo F (2008) Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic. Aging Clin Exp Res 20:87–90PubMed

25.

Cartsos VM, Zhu S, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J Am Dent Assoc 139:23–30PubMed

26.

Pazianas M, Blumentals WA, Miller PD (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19:773–779CrossRefPubMed

27.

Bell NH, Bilezikian JP, Bone HG 3rd, Kaur A, Maragoto A, Santora AC (2002) Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 87:2792–2797CrossRefPubMed

28.

Ho AY, Kung AW (2005) Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 39:1428–1433CrossRefPubMed

29.

Kung AW, Yeung SS, Chu LW (2000) The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. Calcif Tissue Int 67:286–290CrossRefPubMed

30.

Leung JY, Ho AY, Ip TP, Lee G, Kung AW (2005) The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone 36:358–364CrossRefPubMed

31.

Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D (2007) Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 25:105–113CrossRefPubMed

32.

Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH (2006) Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women. Metabolism 55:741–747CrossRefPubMed

33.

Wasnich RD, Ross PD, Thompson DE, Cizza G, Yates AJ (1999) Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporos Int 9:455–460CrossRefPubMed

34.

Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C (2006) Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116:115–120CrossRefPubMed

35.

Levin L, Laviv A, Schwartz-Arad D (2007) Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 138:1218–1220PubMed

36.

Malden NJ, Pai AY (2007) Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 203:93–97CrossRefPubMed

37.

Nase JB, Suzuki JB (2006) Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 137:1115–1119 quiz 1169-1170PubMed

38.

Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18:1363–1370CrossRefPubMed

39.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491CrossRefPubMed

40.

Grant BT, Amenedo C, Freeman K, Kraut RA (2008) Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 66:223–230CrossRefPubMed

41.

Bell BM, Bell RE (2008) Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 66:1022–1024CrossRefPubMed

42.

Wang HL, Weber D, McCauley LK (2007) Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 78:584–594CrossRefPubMed

Title: Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases
Authors: W. Park
N.-K. Kim
M.-Y. Kim
Y.-M. Rhee
H. J. Kim
Publication date: 01-03-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 3/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0973-3

At a glance: The STEP trials

Springer Medicine

Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2010

The relationship between low bone mass and metabolic syndrome in Korean women

Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

Association between vitamin D receptor gene polymorphisms, falls, balance and muscle power: results from two independent studies (APOSS and OPUS)

Does inadequate diet during childhood explain the higher high fracture rates in the Southern United States?

Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006